-
公开(公告)号：WO2022072491A1
公开(公告)日：2022-04-07
申请号：PCT/US2021/052645
申请日：2021-09-29
申请人： METACRINE, INC.
发明人： GOVEK, Steven P. , LAI, Andiliy G. , HUDSON, Andrew R. , SMITH, Nicholas D. , FASANYA, Karensa L.
IPC分类号： A61K31/34 , A61K31/39 , A61K31/40 , A61K31/537 , A61P29/00
摘要： Described herein are compounds that are HSD17B13 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with HSD17B13 activity.
-
公开(公告)号：WO2021222308A1
公开(公告)日：2021-11-04
申请号：PCT/US2021/029473
申请日：2021-04-27
申请人： METACRINE, INC.
发明人： SWANEY, Jamie , CHEN, Hubert , SMITH, Nicholas D. , SONG, Kenneth
IPC分类号： A61K31/166 , A61K31/18 , A61K31/351
摘要： Described herein are methods of treatment of diseases and disorders with semicarbazide-sensitive amine oxidase (SSAO) inhibitors.
-
公开(公告)号：WO2021188692A1
公开(公告)日：2021-09-23
申请号：PCT/US2021/022790
申请日：2021-03-17
申请人： METACRINE, INC.
摘要： Described herein is the farnesoid X receptor agonist, 4-((4-(1-(tert-butyl)-1H-pyrazol-4-yl)pyridin-2-yl)((4-(4-methoxy-3-methylphenyl)bicyclo[2.2.2]octan-1-yl)methyl)carbamoyl)cyclohexyl 3-hydroxyazetidine-trans-1-carboxylate, including crystalline forms and pharmaceutically acceptable salts, solvates, and formulations thereof.
-
公开(公告)号：WO2020061117A1
公开(公告)日：2020-03-26
申请号：PCT/US2019/051607
申请日：2019-09-17
申请人： METACRINE, INC.
发明人： SMITH, Nicholas, D. , GOVEK, Steven, P. , NAGASAWA, Johnny, Y. , LAI, Andiliy, G. , DOUGLAS, Karensa, L.
IPC分类号： A61K31/16 , A61K31/4427 , C07D401/04 , C07D401/14
摘要： Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
-
公开(公告)号：WO2019241751A1
公开(公告)日：2019-12-19
申请号：PCT/US2019/037380
申请日：2019-06-14
申请人： METACRINE, INC.
IPC分类号： A61K31/137 , A61K31/381 , C07C217/62
摘要： Described herein are compounds that are semicarbazide-sensitive amine oxidase (SSAO) inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in treating or preventing a liver disease or condition.
-
公开(公告)号：WO2022072512A1
公开(公告)日：2022-04-07
申请号：PCT/US2021/052674
申请日：2021-09-29
申请人： METACRINE, INC.
发明人： HUDSON, Andrew R. , GOVEK, Steven P. , NAGASAWA, Johnny Y. , BOTROUS, Iriny , SMITH, Nicholas D. , FASANYA, Karensa L.
IPC分类号： A61K31/34 , A61K31/39 , A61K31/40 , A61K31/537 , A61P29/00
摘要： Described herein are compounds that are HSD17B13 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with HSD17B13 activity.
-
公开(公告)号：WO2021188695A1
公开(公告)日：2021-09-23
申请号：PCT/US2021/022793
申请日：2021-03-17
申请人： METACRINE, INC.
摘要： Described herein are pharmaceutical formulations of a farnesoid X receptor agonist, 4-((4-(1-(tert-butyl)-1H-pyrazol-4-yl)pyridin-2-yl)((4-(4-methoxy-3-methylphenyl)bicyclo[2.2.2]octan-1-yl)methyl)carbamoyl)cyclohexyl 3-hydroxyazetidine-trans-1-carboxylate, and methods of using such pharmaceutical formulations in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
-
公开(公告)号：WO2021188690A1
公开(公告)日：2021-09-23
申请号：PCT/US2021/022788
申请日：2021-03-17
申请人： METACRINE, INC.
IPC分类号： A61K31/415 , C07D231/12 , A61P1/16
摘要： Described herein is the use of farnesoid X receptor (FXR) agonists, alone or in combination with additional therapies, in the treatment or prevention of diseases, conditions, or disorders that would benefit from therapy with a FXR agonist.
-
公开(公告)号：WO2021188688A1
公开(公告)日：2021-09-23
申请号：PCT/US2021/022786
申请日：2021-03-17
申请人： METACRINE, INC.
IPC分类号： A61K31/422 , A61K31/4245 , A61K31/428
摘要： Described herein is the use of farnesoid X receptor (FXR) agonists, alone or in combination with additional therapies, in the treatment or prevention of diseases, conditions, or disorders that would benefit from therapy with a FXR agonist.
-
公开(公告)号：WO2020061116A1
公开(公告)日：2020-03-26
申请号：PCT/US2019/051606
申请日：2019-09-17
申请人： METACRINE, INC.
发明人： SMITH, Nicholas, D. , GOVEK, Steven, P. , NAGASAWA, Johnny, Y. , LAI, Andiliy, G. , DOUGLAS, Karensa, L.
IPC分类号： A61K31/42 , A61K31/44 , A61K31/496
摘要： Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
-
-
-
-
-
-
-
-
-
搜索结果
29 条记录 (耗时 0.013 秒)
